Information Provided By: 
Fly News Breaks for June 25, 2018
MNK, DEPO
Jun 25, 2018 | 08:54 EDT
Mizuho analyst Irina Koffler says her physician checks give her more conviction about her thesis on Depomed (DEPO), stating that its cosyntropin opportunity may be underappreciated while investors focus on its older products. She imagines that Mallinckrodt's (MNK) Acthar may need to be discounted if the cosyntropin synthetic launches, Koffler added. She maintains a Buy rating on Depomed shares.
News For DEPO;MNK From the Last 2 Days
There are no results for your query DEPO;MNK
